The Role of Oral Glutathione on Growth Parameters in Children With Cystic Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 14, 2017

Primary Completion Date

December 12, 2018

Study Completion Date

December 12, 2018

Conditions
Cystic Fibrosis
Interventions
DRUG

Oral Glutathione

Oral Glutathione oral powder

DRUG

Placebo

Placebo oral powder

Trial Locations (18)

10032

Childrens Hospital of New York/Columbia University Medical Center, New York

14222

Women and Childrens Hospital of Buffalo, Buffalo

22908

University of Virginia Health System, Charlottesville

30324

Emory University Hospital, Atlanta

32207

Nemours Childrens Clinic, Jacksonville

32504

Nemours Children's Clinic, Pensacola

46202

Riley Children's Hospital, Indianapolis

48201

Childrens Hospital of Michigan, Detroit

49503

Helen DeVos Women and Childrens Center, Grand Rapids

53226

Childrens Hospital of Milwaukee, Milwaukee

55414

University of Minnesota Medical Center, Minneapolis

64108

The Childrens Mercy Hospital, Kansas City

75390

UT Southwestern Medical Center, Dallas

77030

Baylor College of Medicine, Houston

80045

Childrens Hospital Colorado, Aurora

97239

Oregon Health & Science University, Portland

06107

Connecticut Childrens Medical Center, Hartford

05401

The University of Vermont Inc., Burlington

All Listed Sponsors
collaborator

Cystic Fibrosis Foundation

OTHER

lead

University of Minnesota

OTHER

NCT03020719 - The Role of Oral Glutathione on Growth Parameters in Children With Cystic Fibrosis | Biotech Hunter | Biotech Hunter